Indications

Remsima^® is indicated for adult patients with the following conditions:

Indication*	Posology	Special dosing instructions
Moderate to severe Crohn’s Disease in patients who have an inadequate response to conventional therapies.	IV infliximab induction with 5 mg/kg at week 0 and at week 2 SC maintenance with Remsima^® 120 mg dose every 2 weeks, starting from Week 6
Refractory fistulising Crohn’s Disease
Moderately severe to severely active Ulcerative Colitis in patients who have an inadequate response to conventional therapies.
Active Ankylosing Spondylitis
Active and progressive Psoriatic Arthritis in patients who have responded inadequately to disease-modifying anti-rheumatic drug (DMARD) therapy.		May be given in combination with MTX
Moderate to severe Plaque Psoriasis for patients in whom phototherapy or conventional systemic treatments have been inadequate or are inappropriate
Rheumatoid Arthritis patients with active disease despite treatment with methotrexate (MTX) patients with active disease who have not previously received methotrexate.	IV induction with 3 mg/kg at week 0 and at week 2 SC maintenance with 120 mg dose every 2 weeks, starting from Week 6	Must be given concomitantly with MTX

* For subcutaneous injection, 120 mg is fixed dose for all indications.

PBS Information:

Authority required. Refer to PBS Schedule for full authority information.

BEFORE PRESCRIBING, PLEASE REVIEW FULL PRODUCT INFORMATION AVAILABLE HERE.

IV, intravenous; MTX, methotrexate; SC, subcutaneous